Biotech megarounds dominate as $9.1B flows, leaving early-stage startups behind
The biotech venture market is splitting in two: established clinical-stage companies are raising megafunds at a blistering pace, while preclinical and seed-stage biotechs face a deepening funding winter. The contrast underscores a structural shift in startup financing strategies.